Citations

Clear

585 citation(s) found for "Tran, T".

On-Demand Automated Peritoneal Dialysis Solution Generation
Aslam, Nabeel , Edwards, Clinton , Yamagata, Lara Marie, Wellings, Anders J., Wilmington, Alyssa, Uribarri, Jaime , Tran, Ha

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: 325-325

10.1681/asn.20213210s1325b Get It

Validating a Computable Phenotype for Nephrotic Syndrome in Children and Adults Using PCORnet Data
Marchel, Dorota , Tran, Cheryl L. , Greco, Jessica , Denburg, Michelle , Oliverio, Andrea L. , Ayoub, Isabelle , Almaani, Salem , Gipson, Debbie S , Mariani, Laura H.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 582-582

10.1681/asn.20203110s1582b Get It

Semaphorin 3B-Associated Membranous Nephropathy
Sethi, Sanjeev , Charlesworth, M. Cristine , Gross, LouAnn, Buob, David , Tran, Cheryl L. , Emma, Francesco , Dêbiec, Hanna , Madden, Benjamin J. , Vivarelli, Marina , Ravindran, Aishwarya , Diomedi‐Camassei, Francesca , Fervenza, Fernando C. , Ronco, Pierre Marie

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 25-25

10.1681/asn.20203110s125c Get It

Ganglioglioma with anaplastic/high-grade transformation: Histopathologic, molecular, and epigenetic characterization of 3 cases
Vizcaíno, M. Adelita , Giannini, Caterina , Lalich, Daniel, Jenkins, Robert B. , Tran, Quynh T. , Abdullaev, Zied , Aldape, Kenneth , Vaubel, Rachael A. , Aldape, Kenneth , Vaubel, Rachael A , Giannini, Caterina , Nael, Ali , Orr, Brent A.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | May 3, 2024 | Volume: 83 | Issue: 6 | Pages: 416-424

10.1093/jnen/nlae038 | PMID 38699943 Get It

Abstract Ganglioglioma (GG) with anaplasia (anaplastic ganglioglioma) is a rare and controversial diagnosis. When present, anaplasia involves the glial component of the tumor, either at presentation or at recurrence. To date, most published cases lack molecular characterization. We describe the histologic and molecular features of 3 patients presenting with BRAF p. V600E-mutant GG (CNS WHO grade 1) with high-grade glial transformation at recurrence. The tumors occurred in pediatric patients (age 9–16 years) with time to recurrence from 20 months to 7 years. At presentation, each tumor was low-grade, with a BRAFV600E-positive ganglion cell component and a glial component resembling pleomorphic xanthoastrocytoma (PXA) or fibrillary astrocytoma. At recurrence, tumors resembled anaplastic PXA or high-grade astrocytomas without neuronal differentiation. CDKN2A homozygous deletion (HD) was absent in all primary tumors. At recurrence, 2 cases acquired CDKN2A HD; the third case showed loss of p16 and MTAP immunoexpression, but no CDKN2A/B HD or mutation was identified. By DNA methylation profiling, all primary and recurrent tumors either grouped or definitely matched to different methylation classes. Our findings indicate that malignant progression of the glial component can occur in GG and suggest that CDKN2A/B inactivation plays a significant role in this process.
Feminizing Gender Affirming Breast Surgery: Procedural Outcomes at a Single Academic Institution
Figueroa, Nicole Sanchez, Fahradyan, Vahe , Tran, Nho V. , Martinez‐Jorge, Jorys, Figueroa, Nicole Gabriela Sanchez , Fahradyan, Vahe , Sanchez Figueroa, Nicole Gabriela , Kuruoglu, Doga , Sharaf, Basel

Mayo Clinic

Aesthetic Surgery Journal Open Forum | April 26, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/asjof/ojae032 | PMID 38813116 Get It

Abstract Background Implant-based breast augmentation is a gold standard procedure for transfeminine patients to create a more feminine-appearing chest. In many cases, ancillary procedures are performed simultaneously to achieve an optimal aesthetic result. Objectives To determine the clinical outcomes of patients undergoing feminizing gender-affirming breast surgery in a single academic institution. Methods A retrospective electronic chart review of feminizing gender-affirming breast surgery patients at Mayo Clinic, Rochester from 2017 to 2022 was conducted. Patients demographics and surgical outcomes were gathered. A survival analysis was performed to obtain the time-to-event complication rate. Results Over 5 years, 46 patients (92 breasts) were included. The mean age was 39 years (SD ±15), and most had an above-normal Body Mass Index (58.7%). Thirty (65%) had previous gender-affirming surgeries. The mean implant volume was 289 ml (SD ±95; 140 - 520). Most implants were placed in a subglandular plane (81%) with an inframammary fold incision (91.3%). All implants used were smooth round cohesive silicone gel implants. Ancillary procedures were performed in thirty-two patients (69.57%). Eight patients presented complications (4 major vs 4 minor) in a median postoperative follow-up of 372 vs 392 days; at 1-month follow-up, the probability of a complication to have occurred is 2.17% (95% CI: 0–6.3%) vs 5% (95% CI: 0–11.5%) and at 1 year is 10.21% (95% CI: 0–20.9%) vs 12.5% (95% CI: 0–23.4%) ​which remain the same up to 4 years. Conclusions Breast augmentation with implants is a safe procedure to achieve feminization of the breast with a low rate of complications.
Biologically-informed deep neural networks provide quantitative assessment of intratumoral heterogeneity in post-treatment glioblastoma
Li, Jing , Boyett, Deborah , Save, Akshay , Savage, William , Hu, Leland , Bruce, Jeffrey N. , Swanson, Kristin R. , Canoll, Peter , Petridis, Petros , Jackson, Pamela , Hawkins-Daarud, Andrea, Tran, Nhan, Grinband, Jack , Swanson, Kristin R

Mayo Clinic

No container title available | March 27, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3891425/v1 | PMID 38585856 Get It

Abstract Intratumoral heterogeneity poses a significant challenge to the diagnosis and treatment of glioblastoma (GBM). This heterogeneity is further exacerbated during GBM recurrence, as treatment-induced reactive changes produce additional intratumoral heterogeneity that is ambiguous to differentiate on clinical imaging. There is an urgent need to develop non-invasive approaches to map the heterogeneous landscape of histopathological alterations throughout the entire lesion for each patient. We propose to predictively fuse Magnetic Resonance Imaging (MRI) with the underlying intratumoral heterogeneity in recurrent GBM using machine learning (ML) by leveraging image-localized biopsies with their associated locoregional MRI features. To this end, we develop BioNet, a biologically-informed neural network model, to predict regional distributions of three tissue-specific gene modules: proliferating tumor, reactive/inflammatory cells, and infiltrated brain tissue. BioNet offers valuable insights into the integration of multiple implicit and qualitative biological domain knowledge, which are challenging to describe in mathematical formulations. BioNet performs significantly better than a range of existing methods on cross-validation and blind test datasets. Voxel-level prediction maps of the gene modules by BioNet help reveal intratumoral heterogeneity, which can improve surgical targeting of confirmatory biopsies and evaluation of neuro-oncological treatment effectiveness. The non-invasive nature of the approach can potentially facilitate regular monitoring of the gene modules over time, and making timely therapeutic adjustment. These results also highlight the emerging role of ML in precision medicine.
Insights Into Eye Care Accessibility: Geospatial Distribution of Eye Care Providers and Socioeconomic Factors by ZIP Code
Tran, Meagan , Gonzalez, Valeria , Mead‐Harvey, Carolyn , Shen, Joanne F , Tran, Meagan T , Gonzalez, Valeria V

Mayo Clinic

Translational Vision Science & Technology | March 26, 2024 | Volume: 13 | Issue: 3 | Pages: 21

10.1167/tvst.13.3.21 | PMID 38530303 Get It

NAB2::STAT6 fusions and genome‐wide DNA methylation profiling: Predictors of patient outcomes in meningeal solitary fibrous tumors
Eschbacher, Kathryn L. , Tran, Quynh T. , Moskalev, Evgeny A. , Jenkins, Sarah M. , Fritchie, Karen , Stoehr, Robert , Caron, Alissa, Link, Michael J., Brown, Paul D. , Guajardo, Andrew, Wu, Ashley, Louis, David N. , Kaplan, Alexander , Ferrarese, Fabio, Raleigh, David R. , Nguyen, Minh , Gross, John , Vega, Jose Velazquez, Haller, Florian , Louis, David N , Giannini, Caterina , Link, Michael J. , Brat, Daniel J. , Santagata, Sandro , Brastianos, Priscilla K. , Alexander, Brian M. , Rossi, Sabrina , Vega, José E. Velázquez , Rodríguez, Fausto J. , Perry, Arie , Martinez‐Lage, Maria , Orr, Brent A. , Giannini, Caterina

Mayo Clinic

Brain Pathology | March 25, 2024 | Volume: 34 | Issue: 6 | Pages: No page available

10.1111/bpa.13256 | PMID 38523251 Get It

AbstractMeningeal solitary fibrous tumors (SFT) are rare and have a high frequency of local recurrence and distant metastasis. In a cohort of 126 patients (57 female, 69 male; mean age at surgery 53.0 years) with pathologically confirmed meningeal SFTs with extended clinical follow‐up (median 9.9 years; range 15 days–43 years), we performed extensive molecular characterization including genome‐wide DNA methylation profiling (n = 80) and targeted TERT promoter mutation testing (n = 98). Associations were examined with NAB2::STAT6 fusion status (n = 101 cases; 51 = ex5‐7::ex16‐17, 26 = ex4::ex2‐3; 12 = ex2‐3::exANY/other and 12 = no fusion) and placed in the context of 2021 Central Nervous System (CNS) WHO grade. NAB2::STAT6 fusion breakpoints (fusion type) were significantly associated with metastasis‐free survival (MFS) (p = 0.03) and, on multivariate analysis, disease‐specific survival (DSS) when adjusting for CNS WHO grade (p = 0.03). DNA methylation profiling revealed three distinct clusters: Cluster 1 (n = 38), Cluster 2 (n = 22), and Cluster 3 (n = 20). Methylation clusters were significantly associated with fusion type (p < 0.001), with Cluster 2 harboring ex4::ex2‐3 fusion in 16 (of 20; 80.0%), nearly all TERT promoter mutations (7 of 8; 87.5%), and predominantly an “SFT” histologic phenotype (15 of 22; 68.2%). Clusters 1 and 3 were less distinct, both dominated by tumors having ex5‐7::ex16‐17 fusion (respectively, 25 of 33; 75.8%, and 12 of 18; 66.7%) and with variable histological phenotypes. Methylation clusters were significantly associated with MFS (p = 0.027), but not overall survival (OS). In summary, NAB2::STAT6 fusion type was significantly associated with MFS and DSS, suggesting that tumors with an ex5::ex16‐17 fusion may have inferior patient outcomes. Methylation clusters were significantly associated with fusion type, TERT promoter mutation status, histologic phenotype, and MFS.
Abstract 5562: Altered tumor microenvironment in animal model of concomitant GBM and Alzheimer's pathology
Nascari, David , Eghlimi, Ryan , Alton, Drake, Fryer, John Denis , Tran, Nhan L. , Tran, Nhan L , Beniwal, Angad

Mayo Clinic

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 5562-5562

10.1158/1538-7445.am2024-5562 Get It

Abstract Glioblastoma (GBM) and Alzheimer’s disease (AD) are two devastating central nervous system diagnoses with no known cure. Both diseases are associated with advanced age. The majority of GBM tumors form in the frontal and temporal lobes, two of the brain regions most impacted by amyloid and tau pathology in AD. Females have a higher risk of AD, while males have a higher risk of GBM. Several large case series have established epidemiological evidence that the two diseases are inversely correlated. Nevertheless, it remains unknown whether presence of subclinical amyloid or tau pathology antagonizes the establishment or progression of GBM. The present study sought to characterize GBM growth, progression, and immune response in the setting of concomitant AD pathology using the syngeneic murine GL261 tumor model. To further understand the tumor cell changes that occur in the presence or absence of AD pathology, we engineered GL261 with a dual-tagged vector consisting of RiboTag (to allow for full-length mRNA profiling) and TurboID (to allow for proteomic profiling). GL261 cells were injected intracranially into APPNL-G-F/NL-G-F - MAPThuman/human, APPNL-G-F/+ - MAPThuman/+, and wildtype C57BL/6J mice. Tumors in both wildtype and AD conditions contained ~50% intratumoral myeloid cells (Iba+, P2RY12-). Differential activation of intratumoral myeloid cells will be assessed with immunohistochemistry. Microgliosis (IBA1, P2RY12) and astrogliosis (GFAP) around the tumor in the setting of Alzheimer’s pathology versus normal conditions will be compared. Invasiveness, proliferation, DNA damage (pH2AX), and apoptosis (cleaved PARP, cleaved Caspase 3) will be compared. Tumor cell-specific changes unique to tumors in the AD microenvironment will be assessed transcriptionally with RiboTag profiling as well as proteomically with TurboID purifications. Our preliminary data suggests that the presence of concomitant AD pathology affects GBM growth and progression as well as the immune response to the tumor, and warrants further investigation. Citation Format: David Nascari, Ryan Eghlimi, Angad Beniwal, Drake Alton, John Fryer, Nhan L. Tran. Altered tumor microenvironment in animal model of concomitant GBM and Alzheimer's pathology [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5562.
Abstract 5905: Propentofylline enhances GBM sensitivity to temozolomide via targeting TROY signaling
Eghlimi, Ryan , Nascari, David , Alton, Drake, Grief, Dustin, Loftus, Joseph C. , Haluska, M., Tran, Nhan L. , Tran, Nhan L , Beniwal, Angad , Coleman, David

Mayo Clinic

Cancer Research | March 22, 2024 | Volume: 84 | Issue: 6_Supplement | Pages: 5905-5905

10.1158/1538-7445.am2024-5905 Get It

Abstract Glioblastoma (GBM) is a high grade glioma that accounts for the majority of primary malignant brain tumors. The standard of care for GBM consists of maximal surgical resection, concurrent radiation and temozolomide (TMZ), and adjuvant TMZ. However, this has only led to a modest increase in median patient survival. TROY (TNFRSF19) is an orphan member of the TNF receptor superfamily that is differentially upregulated in GBM with low expression in normal brain tissue. Previously, we have reported that TROY is overexpressed in GBM and signals to mediate cell invasion and therapeutic resistance. Propentofylline (PPF) is a well-studied synthetic methylxanthine derivative that has strong BBB penetrance. We have shown that PPF decreases TROY expression in gliomas, inhibits invasion, and sensitizes GBM to TMZ in vitro. Here we examined the efficacy of PPF in combination with TMZ using in vivo studies of intracranial models of GBM patient-derived xenograft (PDX) models in murine. We tested 3 models of GBM PDX cells with various TROY expression levels (GBM8-high TROY; GBM43-moderate TROY; GBM22-low/no TROY). Our intracranial PDX experiments showed that PPF treatment alone did not increase survival in all PDX cells. The combination of PPF and TMZ treatment did provide a survival benefit (p &lt; 0.039) relative to TMZ alone (only in GBM8-high TROY and GBM43-moderate TROY) that was partially lost when treatment was discontinued. However, continuous PPF administration following a concomitant PPF and TMZ treatment course led to extended survival (p &lt; 0.0015) compared to TMZ alone resulting in increased DNA damage (γH2AX) and apoptotic markers (Cleaved Caspase-3). Immunohistochemical analyses showed that TROY expression was decreased in tumors treated with PPF. In addition, PPF-treated tumors showed a differential myeloid population with well circumscribed tumors as compared to control-treated or TMZ-treated tumors. Thus, our data demonstrates that PPF may provide a pharmacological approach to targeting TROY concomitant with standard-of-care to increase patient survival. Citation Format: Ryan Eghlimi, David Nascari, Angad Beniwal, Drake Alton, Dustin Grief, Joseph Loftus, Melanie Haluska, David Coleman, Nhan Tran. Propentofylline enhances GBM sensitivity to temozolomide via targeting TROY signaling [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5905.